Cell signaling by receptor tyrosine kinases, Cell, vol.103, pp.211-225, 2000. ,
Signal transduction and the control of gene expression, Science, vol.295, pp.813-818, 2002. ,
Oncogenic kinase signalling, Nature, vol.411, pp.355-365, 2001. ,
Signal transduction by receptors with tyrosine kinase activity, Cell, vol.61, pp.203-212, 1990. ,
Deep surveying of alternative splicing complexity in the human transcriptome by high-throughput sequencing, Nat. Genet, vol.40, pp.1413-1415, 2008. ,
A global view of gene activity and alternative splicing by deep sequencing of the human transcriptome, Science, vol.321, pp.956-960, 2008. ,
Alternative pre-mRNA splicing regulation in cancer: Pathways and programs unhinged, Genes Dev, vol.24, pp.2343-2364, 2010. ,
Exon III splicing of fibroblast growth factor receptor 1 is modulated by growth factors and cyclin D1, Pancreas, vol.37, pp.159-164, 2008. ,
Identification and characterization of ALK kinase splicing isoforms in non-small-cell lung cancer, J. Thorac. Oncol, vol.9, pp.248-253, 2014. ,
AXL, a transforming gene isolated from primary human myeloid leukemia cells, encodes a novel receptor tyrosine kinase, Mol. Cell. Biol, vol.11, pp.5016-5031, 1991. ,
The discoidin domain receptor tyrosine kinases are activated by collagen, Mol. Cell, vol.1, pp.13-23, 1997. ,
EGFR soluble isoforms and their transcripts are expressed in meningiomas, PLoS ONE, vol.7, 2012. ,
URL : https://hal.archives-ouvertes.fr/hal-00872638
The epidermal growth factor receptor variant III (EGFRvIII): Where wild things are altered, FEBS J, vol.280, pp.5350-5370, 2013. ,
Current therapeutic advances targeting EGFR and EGFRvIII in glioblastoma. Front, Oncol, vol.5, 2015. ,
A novel epidermal growth factor receptor variant lacking multiple domains directly activates transcription and is overexpressed in tumors, Oncogene, vol.31, pp.2953-2967, 2012. ,
Isoform-specific monoubiquitination, endocytosis, and degradation of alternatively spliced ErbB4 isoforms, Proc. Natl. Acad. Sci, vol.105, pp.4162-4167, 2008. ,
Alternatively spliced FGFR-1 isoforms differentially modulate endothelial cell activation of c-YES, Arch. Biochem. Biophys, vol.450, pp.50-62, 2006. ,
Cellular signaling by fibroblast growth factor receptors, Cytokine Growth Factor Rev, vol.16, pp.139-149, 2005. ,
Insulin receptor alternative splicing is regulated by insulin signaling and modulates ? cell survival, Sci. Rep, vol.6, p.31222, 2016. ,
Activation of met via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to met inhibitors, Cancer Discov, vol.5, pp.850-859, 2015. ,
MET exon 14 skipping defines a unique molecular class of non-small cell lung cancer, Oncotarget, vol.7, pp.41691-41702, 2016. ,
Alternative splicing results in RET isoforms with distinct trafficking properties, Mol. Biol. Cell, vol.23, pp.3838-3850, 2012. ,
Pro-metastatic splicing of ron proto-oncogene mrna can be reversed: Therapeutic potential of bifunctional oligonucleotides and indole derivatives, RNA Biol, vol.7, pp.495-503, 2010. ,
URL : https://hal.archives-ouvertes.fr/hal-02193461
Novel splicing variants of recepteur d'origine nantais (RON) tyrosine kinase involving exons 15-19 in lung cancer, Lung Cancer, vol.92, pp.41-46, 2016. ,
TRKing down an old oncogene in a new era of targeted therapy, Cancer Discov, vol.5, pp.25-34, 2015. ,
Identification of a natural soluble form of the vascular endothelial growth factor receptor, FLT-1, and its heterodimerization with KDR, Biochem. Biophys. Res. Commun, vol.226, pp.324-328, 1996. ,
Induction of antagonistic soluble decoy receptor tyrosine kinases by intronic polyA activation, Mol. Cell, vol.43, pp.927-939, 2011. ,
Phase I study of cetuximab, irinotecan, and vandetanib (ZD6474) as therapy for patients with previously treated metastastic colorectal cancer, PLoS ONE, vol.7, 2012. ,
Improved tumor vascularization after anti-VEGF therapy with carboplatin and nab-paclitaxel associates with survival in lung cancer, Proc. Natl. Acad. Sci, vol.112, pp.1547-1552, 2015. ,
Receptor specificity of the fibroblast growth factor family. The complete mammalian FGF family, J. Biol. Chem, vol.281, pp.15694-15700, 2006. ,
Exon switching and activation of stromal and embryonic fibroblast growth factor (FGF)-FGF receptor genes in prostate epithelial cells accompany stromal independence and malignancy, Mol. Cell. Biol, vol.13, pp.4513-4522, 1993. ,
Involvement of fibroblast growth factor receptor 2 isoform switching in mammary oncogenesis, Mol. Cancer Res, vol.6, pp.435-445, 2008. ,
Altered expression of the RON receptor tyrosine kinase in primary human colorectal adenocarcinomas: Generation of different splicing RON variants and their oncogenic potential, Oncogene, vol.22, pp.186-197, 2003. ,
An oncogenic isoform of HER2 associated with locally disseminated breast cancer and trastuzumab resistance, Mol. Cancer Ther, vol.8, pp.2152-2162, 2009. ,
Epidermal growth factor receptor: Mechanisms of activation and signalling, Exp. Cell Res, vol.284, pp.31-53, 2003. ,
Structure-based view of epidermal growth factor receptor regulation, Annu. Rev. Biophys, vol.37, pp.353-373, 2008. ,
Shedding of epidermal growth factor receptor is a regulated process that occurs with overexpression in malignant cells, Exp. Cell Res, vol.314, pp.2907-2918, 2008. ,
Generation of novel, secreted epidermal growth factor receptor (EGFR/ErbB1) isoforms via metalloprotease-dependent ectodomain shedding and exosome secretion, J. Cell. Biochem, vol.103, pp.1783-1797, 2008. ,
A 1.8 kb alternative transcript from the human epidermal growth factor receptor gene encodes a truncated form of the receptor, Nucleic Acids Res, vol.24, pp.4050-4056, 1996. ,
URL : https://hal.archives-ouvertes.fr/in2p3-00024414
Comparative genomic sequence analysis and isolation of human and mouse alternative EGFR transcripts encoding truncated receptor isoforms, Genomics, vol.71, pp.1-20, 2001. ,
An alternatively processed mRNA from the avian c-erbB gene encodes a soluble, truncated form of the receptor that can block ligand-dependent transformation, Mol. Cell. Biol, vol.12, pp.883-893, 1992. ,
Soluble epidermal growth factor receptor (sEGFR/sErbB1) as a potential risk, screening, and diagnostic serum biomarker of epithelial ovarian cancer, Cancer Epidemiol. Biomark. Prev, vol.12, pp.103-113, 2003. ,
Serum epidermal growth factor receptor and HER2 expression in primary and metastatic breast cancer patients, Breast Cancer Res, vol.9, 2007. ,
Soluble epidermal growth factor receptors (sEGFRS) in cancer: Biological aspects and clinical relevance, Int. J. Mol. Sci, 2016. ,
Alteration of the serum levels of the epidermal growth factor receptor and its ligands in patients with non-small cell lung cancer and head and neck carcinoma, Br. J. Cancer, vol.96, pp.1569-1578, 2007. ,
Detection of epidermal growth factor receptor in the serum of gastric carcinoma patients, vol.79, pp.1879-1883, 1997. ,
Analysis of the prognostic value of soluble epidermal growth factor receptor plasma concentration in advanced non-small-cell lung cancer patients, Clin. Lung Cancer, vol.12, pp.320-327, 2011. ,
Preliminary evidence on the diagnostic and molecular role of circulating soluble EGFR in non-small cell lung cancer, Int. J. Mol. Sci, vol.16, 2015. ,
Epidermal growth factor receptor serum (sEGFR) level may predict response in patients with EGFR-positive advanced colorectal cancer treated with gefitinib?, Cancer Chemother. Pharmacol, vol.63, pp.139-148, 2008. ,
Prognostic and predictive impact of soluble epidermal growth factor receptor (sEGFR) protein in the serum of patients treated with chemotherapy for metastatic breast cancer, Anticancer Res, vol.26, pp.1479-1487, 2006. ,
Oncogenic EGFR signaling networks in glioma, Sci. Signal, 2009. ,
A common mutant epidermal growth factor receptor confers enhanced tumorigenicity on human glioblastoma cells by increasing proliferation and reducing apoptosis, Cancer Res, vol.56, pp.5079-5086, 1996. ,
Genes for epidermal growth factor receptor, transforming growth factor ?, and epidermal growth factor and their expression in human gliomas in vivo, Cancer Res, vol.51, pp.2164-2172, 1991. ,
Frequent expression of a mutant epidermal growth factor receptor in multiple human tumors, Cancer Res, vol.55, pp.5536-5539, 1995. ,
Expression of activated epidermal growth factor receptors, Ras-guanosine triphosphate, and mitogen-activated protein kinase in human glioblastoma multiforme specimens, Neurosurgery, vol.45, pp.1442-1453, 1999. ,
Prognostic significance of overexpression and phosphorylation of epidermal growth factor receptor (EGFR) and the presence of truncated EGFRvIII in locoregionally advanced breast cancer, J. Clin. Oncol, vol.25, pp.4405-4413, 2007. ,
Evidence of high incidence of EGFRvIII expression and coexpression with EGFR in human invasive breast cancer by laser capture microdissection and immunohistochemical analysis, Int. J. Cancer, vol.98, pp.357-361, 2002. ,
The plasticity of oncogene addiction: Implications for targeted therapies directed to receptor tyrosine kinases, Neoplasia, vol.11, pp.448-458, 2009. ,
Targeting a glioblastoma cancer stem-cell population defined by EGF receptor variant III, Cancer Res, vol.74, pp.1238-1249, 2014. ,
Inverse correlation of epidermal growth factor receptor messenger RNA induction and suppression of anchorage-independent growth by OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in glioblastoma multiforme cell lines, J. Neurosurg, vol.100, pp.523-533, 2004. ,
The EGFRvIII variant in glioblastoma multiforme, J. Clin. Neurosci, vol.16, pp.748-754, 2009. ,
Activity of anti-epidermal growth factor receptor monoclonal antibody c225 against glioblastoma multiforme, Neurosurgery, vol.51, pp.1005-1014, 2002. ,
A phase II study of anti-epidermal growth factor receptor radioimmunotherapy in the treatment of glioblastoma multiforme, J. Neurosurg, vol.113, pp.192-198, 2010. ,
Suppression of EGFR expression by antisense or small interference RNA inhibits U251 glioma cell growth in vitro and in vivo, Cancer Gene Ther, vol.13, pp.530-538, 2006. ,
A naturally occurring mutant human epidermal growth factor receptor as a target for peptide vaccine immunotherapy of tumors, Cancer Res, vol.57, pp.1419-1424, 1997. ,
Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma, Neuro Oncol, vol.13, pp.324-333, 2011. ,
Amplified and rearranged epidermal growth factor receptor genes in human glioblastomas reveal deletions of sequences encoding portions of the N-and/or C-terminal tails, Proc. Natl. Acad. Sci, vol.89, pp.4309-4313, 1992. ,
EGFRvIV: A previously uncharacterized oncogenic mutant reveals a kinase autoinhibitory mechanism, Oncogene, vol.29, pp.5850-5860, 2010. ,
A novel EGFR isoform confers increased invasiveness to cancer cells, Cancer Res, vol.73, pp.7056-7067, 2013. ,
Weak binding to E3 ubiquitin ligase c-Cbl increases EGFRvA protein stability, FEBS Lett, vol.590, pp.1345-1353, 2016. ,
VEGF signaling inside vascular endothelial cells and beyond, Curr. Opin. Cell Biol, vol.24, pp.188-193, 2012. ,
VEGF-A mRNA processing, stability and translation: A paradigm for intricate regulation of gene expression at the post-transcriptional level, Nucleic Acids Res, vol.41, pp.7997-8010, 2013. ,
Hallmarks of alternative splicing in cancer, Oncogene, vol.33, pp.5311-5318, 2014. ,
Vascular endothelial growth factor: Basic science and clinical progress, Endocr. Rev, vol.25, pp.581-611, 2004. ,
Vascular endothelial growth factor (VEGF) signaling in tumor progression, Crit. Rev. Oncol. Hematol, vol.62, pp.179-213, 2007. ,
VEGF165b, an inhibitory splice variant of vascular endothelial growth factor, is down-regulated in renal cell carcinoma, Cancer Res, vol.62, pp.4123-4131, 2002. ,
Ballmer-Hofer, K. A VEGF-A splice variant defective for heparan sulfate and neuropilin-1 binding shows attenuated signaling through VEGFR-2, Cell. Mol. Life Sci, vol.63, pp.2067-2077, 2006. ,
Vascular endothelial growth factor (VEGF)-A165b is a weak in vitro agonist for VEGF receptor-2 due to lack of coreceptor binding and deficient regulation of kinase activity, Cancer Res, vol.68, pp.4683-4692, 2008. ,
Alternatively spliced vascular endothelial growth factor receptor-2 is an essential endogenous inhibitor of lymphatic vessel growth, Nat. Med, vol.15, pp.1023-1030, 2009. ,
A recently evolved novel trophoblast-enriched secreted form of fms-like tyrosine kinase-1 variant is up-regulated in hypoxia and preeclampsia, J. Clin. Endocrinol. Metab, vol.94, pp.2524-2530, 2009. ,
Novel splice variants of sFlt1 are upregulated in preeclampsia, Placenta, vol.30, pp.250-255, 2009. ,
Full-length human placental sFlt-1-e15a isoform induces distinct maternal phenotypes of preeclampsia in mice, PLoS ONE, vol.10, p.119547, 2015. ,
Release and complex formation of soluble VEGFR-1 from endothelial cells and biological fluids, Lab. Investig, vol.80, pp.443-454, 2000. ,
Expression of placental FLT1 transcript variants relates to both gestational hypertensive disease and fetal growth, Hypertension, vol.58, pp.70-76, 2011. ,
Hypoxia and sFlt-1 in preeclampsia: The "chicken-and-egg" question, Endocrinology, vol.145, pp.4835-4837, 2004. ,
A novel human-specific soluble vascular endothelial growth factor receptor 1: Cell-type-specific splicing and implications to vascular endothelial growth factor homeostasis and preeclampsia, Circ. Res, vol.102, pp.1566-1574, 2008. ,
Vascular endothelial growth factor (VEGF) and soluble VEGF receptor FLT-1 in diabetic nephropathy, Kidney Int, vol.67, pp.167-177, 2005. ,
Overexpression of soluble vascular endothelial growth factor receptor 1 in colorectal cancer: Association with progression and prognosis, Cancer Sci, vol.98, pp.405-410, 2007. ,
Elevated placental soluble vascular endothelial growth factor receptor-1 inhibits angiogenesis in preeclampsia, Circ. Res, vol.95, pp.884-891, 2004. ,
Autocrine activity of soluble FLT-1 controls endothelial cell function and angiogenesis, Vasc. Cell, 2011. ,
Interleukin-4 and granulocyte-macrophage colony-stimulating factor mediates the upregulation of soluble vascular endothelial growth factor receptor-1 in RAW264.7 cells-a process in which p38 mitogen-activated protein kinase signaling has an important role, J. Microbiol. Immunol. Infect, vol.49, pp.344-351, 2016. ,
Geifman-Holtzman, O. Gadd45a stress signaling regulates sFlt-1 expression in preeclampsia, J. Cell. Physiol, vol.220, pp.632-639, 2009. ,
Placental expression of miR-517a/b and miR-517c contributes to trophoblast dysfunction and preeclampsia, PLoS ONE, vol.10, 2015. ,
Jumonji domain-containing protein 6 (Jmjd6) is required for angiogenic sprouting and regulates splicing of VEGF-receptor 1, Proc. Natl. Acad. Sci, vol.108, pp.3276-3281, 2011. ,
NOTCH decoys that selectively block DLL/NOTCH or JAG/NOTCH disrupt angiogenesis by unique mechanisms to inhibit tumor growth, Cancer Discov, vol.5, pp.182-197, 2015. ,
Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor, Proc. Natl. Acad. Sci, vol.90, pp.10705-10709, 1993. ,
A systems biology perspective on sVEGFR1: Its biological function, pathogenic role and therapeutic use, J. Cell. Mol. Med, vol.14, pp.528-552, 2010. ,
Corneal avascularity is due to soluble VEGF receptor-1, Nature, vol.443, pp.993-997, 2006. ,
Soluble vascular endothelial growth factor receptor-1 contributes to the corneal antiangiogenic barrier, Br. J. Ophthalmol, vol.91, pp.505-508, 2007. ,
Endometrial VEGF induces placental sFLT1 and leads to pregnancy complications, J. Clin. Investig, vol.124, pp.4941-4952, 2014. ,
VEGF receptor signalling-In control of vascular function, Nat. Rev. Mol. Cell Biol, vol.7, pp.359-371, 2006. ,
Postischemic gene transfer of soluble FLT-1 protects against brain ischemia with marked attenuation of blood-brain barrier permeability, J. Cereb. Blood Flow Metab, vol.27, pp.1152-1160, 2007. ,
Soluble vascular endothelial growth factor receptor-1 protects mice in sepsis, Crit. Care Med, vol.35, 1955. ,
Circulating angiogenic factors and the risk of preeclampsia, N. Engl. J. Med, vol.350, pp.672-683, 2004. ,
Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia, J. Clin. Investig, vol.111, pp.649-658, 2003. ,
Increased levels of the soluble variant of the vascular endothelial growth factor receptor VEGFR-1 are associated with a poor prognosis in wound healing, J. Invest. Dermatol, vol.123, pp.799-802, 2004. ,
Circulating angiogenic modulatory factors predict survival and functional class in pulmonary arterial hypertension, Pulm. Circ, vol.3, pp.369-380, 2013. ,
The role of angiogenic factors and their soluble receptors in acute lung injury (ALI)/acute respiratory distress syndrome (ARDS) associated with critical illness, J. Inflamm, vol.10, issue.6, 2013. ,
Paracrine expression of a native soluble vascular endothelial growth factor receptor inhibits tumor growth, metastasis, and mortality rate, Proc. Natl. Acad. Sci, vol.95, pp.8795-8800, 1998. ,
Delivery of soluble VEGF receptor 1 (sFlt1) by gene electrotransfer as a new antiangiogenic cancer therapy, Mol. Pharm, vol.8, pp.701-708, 2011. ,
Suppression of tumor angiogenesis and growth by gene transfer of a soluble form of vascular endothelial growth factor receptor into a remote organ, Cancer Res, vol.60, pp.2169-2177, 2000. ,
Gene transfer of a soluble receptor of VEGF inhibits the growth of experimental eyelid malignant melanoma, Investig. Ophthalmol. Vis. Sci, vol.41, pp.2395-2403, 2000. ,
The VEGF receptor Flt-1 (VEGFR-1) is a positive modulator of vascular sprout formation and branching morphogenesis, Blood, vol.103, pp.4527-4535, 2004. ,
Vascular endothelial growth factor receptor-1 is deposited in the extracellular matrix by endothelial cells and is a ligand for the ?5?1 integrin, J. Cell Sci, vol.116, pp.3479-3489, 2003. ,
Soluble VEGF receptor 1 (sFlt1) induces non-apoptotic death in ovarian and colorectal cancer cells, Sci. Rep, 2016. ,
Expression of the soluble vascular endothelial growth factor receptor-1 in cutaneous melanoma: Role in tumour progression, Br. J. Dermatol, vol.164, pp.1061-1070, 2011. ,
Clinical usefulness of assessing VEGF and soluble receptors sVEGFR-1 and sVEGFR-2 in women with breast cancer, Ann. Agric. Environ. Med, vol.20, pp.293-297, 2013. ,
Levels of soluble vascular endothelial growth factor (VEGF) receptor 1 in astrocytic tumors and its relation to malignancy, vascularity, and VEGF-A. Clin, Cancer Res, vol.9, pp.1399-1405, 2003. ,
Urbanska-Rys, H. Circulating VEGF and its soluble receptors sVEGFR-1 and sVEGFR-2 in patients with acute leukemia, Eur. Cytokine Netw, vol.14, pp.149-153, 2003. ,
Significance of vascular endothelial growth factor (VEGF)/soluble VEGF receptor-1 relationship in breast cancer, Int. J. Cancer, vol.98, pp.14-18, 2002. ,
Soluble Tie2 and Flt1 extracellular domains in serum of patients with renal cancer and response to antiangiogenic therapy, Clin. Cancer Res, 1992. ,
The ratio of serum placenta growth factor to soluble vascular endothelial growth factor receptor-1 predicts the prognosis of hepatocellular carcinoma, Oncol. Rep, vol.23, pp.1647-1654, 2010. ,
Plasma vascular endothelial growth factor dysregulation in defining aggressiveness of head and neck squamous cell carcinoma, J. Oncol, vol.687934, 2012. ,
Functional significance of vascular endothelial growth factor and its receptor (receptor-1) in various lung cancer types, Clin. Biochem, vol.37, pp.840-845, 2004. ,
Serum vascular endothelial growth factor/soluble vascular endothelial growth factor receptor 1 ratio is an independent prognostic marker in pancreatic cancer, Pancreas, vol.37, pp.145-150, 2008. ,
Association between intratumoral free and total VEGF, soluble VEGFR-1, VEGFR-2 and prognosis in breast cancer, Br. J. Cancer, vol.92, pp.553-561, 2005. ,
Soluble VEGF/sFlt1 ratio is an independent predictor of aml patient out come, Hematology, vol.10, pp.131-134, 2005. ,
Markers of response for the antiangiogenic agent bevacizumab, J. Clin. Oncol, vol.31, 2013. ,
Role of vascular density and normalization in response to neoadjuvant bevacizumab and chemotherapy in breast cancer patients, Proc. Natl. Acad. Sci, vol.112, pp.14325-14330, 2015. ,
A phase II and biomarker study of ramucirumab, a human monoclonal antibody targeting the VEGF receptor-2, as first-line monotherapy in patients with advanced hepatocellular cancer, Clin. Cancer Res, vol.19, pp.6614-6623, 2013. ,
Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: A multidisciplinary phase II study, J. Clin. Oncol, vol.27, pp.3020-3026, 2009. ,
Soluble VEGFR-1: A new biomarker of sorafenib-related hypertension (i.e., sorafenib-related is the compound adjective?), J. Clin. Pharmacol, vol.55, pp.478-479, 2015. ,
Plasma soluble VEGFR-1 is a potential dual biomarker of response and toxicity for bevacizumab with chemoradiation in locally advanced rectal cancer, Oncologist, vol.15, pp.577-583, 2010. ,
Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: A phase II study, J. Clin. Oncol, vol.27, pp.3027-3035, 2009. ,
Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: Efficacy and circulating angiogenic biomarkers associated with therapeutic resistance, J. Clin. Oncol, vol.28, pp.453-459, 2010. ,
Novel glycosylated VEGF decoy receptor fusion protein, VEGF-Grab, efficiently suppresses tumor angiogenesis and progression, Mol. Cancer Ther, vol.14, pp.470-479, 2015. ,
Morpholino-mediated increase in soluble Flt-1 expression results in decreased ocular and tumor neovascularization, PLoS ONE, vol.7, 2012. ,
Inhibition of vemurafenib-resistant melanoma by interference with pre-mRNA splicing, Nat. Commun, vol.6, p.7103, 2015. ,
Small molecule modulators of pre-mRNA splicing in cancer therapy, Trends Mol. Med, vol.22, pp.28-37, 2016. ,
Modulation of splicing catalysis for therapeutic targeting of leukemia with mutations in genes encoding spliceosomal proteins, Nat. Med, vol.22, pp.672-678, 2016. ,